Lipoxin A₄: a novel anti-inflammatory molecule?

Arachidonic acid is metabolised by the cyclooxygenase pathway to the prostaglandins and thromboxane A₂ or via one of the lipoxygenase pathways.¹ Three major lipoxygenase pathways have been identified in mammalian tissue – namely, the 5-, 12-, and 15-lipoxygenases.²⁻⁴ The 5-lipoxygenase pathway metabolises arachidonic acid through two intermediates, 5-hydroperoxyeicosatetraenoic acid (5-HPETE) and leukotriene A₄ (LTA₄), to LTB₄ and the sulphidopeptide leukotrienes LTC₄, LTD₄, and LTE₄.⁵ The sulphidopeptide leukotrienes are potent spasmogens⁶ for non-vascular smooth muscle and may play a part in the pathogenesis of bronchial asthma.⁷⁻¹⁰

The interactions between 5-lipoxygenase and 15-lipoxygenase on arachidonic acid metabolism have recently been studied and a new series of biologically active metabolites described.^{11,12} These molecules have been termed lipoxins. Unlike leukotrienes lipoxins possess a conjugated tetraene structure and the stereochemistries of the two major isomers, lipoxin (LX)A₄ and LXB₄, are 5S, 6R, 5S-trihydroxy 7,9,13-*trans*-11-*cis*-eicosatetraenoic acid and 5S, 14R, 15S-trihydroxy-6,10,12-*trans*-8-*cis*-eicosatetraenoic acid, respectively.^{13,14} It is now established that lipoxins can also be generated by an interaction between the 5- and 12-lipoxygenases, when the 12-lipoxygenase acts with a C-15 specificity.

Lipoxins can be generated by human neutrophils, eosinophils, or platelets from both endogenous or exogenous substrates in vitro.^{11,12,15,16} Furthermore, using gas chromatography and mass spectrometry with selective ion monitoring, LXA₄ has been detected in the bronchoalveolar lavage fluid in patients suffering from pulmonary sarcoidosis, infective bronchopneumonia, asthma, and carcinoma of the lung.¹⁷ It was not detected in normal subjects. In patients with detectable LXA₄ in bronchoalveolar lavage fluid, the ratio of the concentrations of LXA₄ to those of sulphidopeptide leukotrienes ranges from 1.9 to 62 (mean 19.0), indicating that LXA₄ is generated in vivo.

In vitro studies with guinea pig parenchymal lung strips have shown that lipoxins exhibit contractile activity.^{18,19} LXA₄ prepared by total chemical synthesis has been shown to constrict parenchymal strips over a concentration range of 1×10^{-8} to 1×10^{-5} M.¹⁹ The contractile activity of LXA₄ was slow in onset and did not plateau for 20 minutes, and was approximately 10 000 times less potent than that of LTD₄. The contraction was not mediated through secondary generation of cyclooxygenase metabolites or secondary release of sulphidopeptide leukotrienes. The activity of LXA₄ may be elicited via an interaction with an LTD₄ receptor. This suggestion was further supported when it was shown that LXA₄ (1×10^{-7} M) prevented mesangial cell inositol triphosphate generation induced by LTD₄.²⁰ At concentrations of 1×10^{-8} M and 5×10^{-8} M LXA₄ induced the generation of mesangial cell inositol triphosphate which was abolished with a sulphidopeptide leukotriene antagonist SK&F 104353. LXA₄ competed with [³H] LTD₄ for specific binding to cultured rat glomerular mesangial cells. In vivo it antagonised LTD₄-induced falls in glomerular filtration rate. Dahlen and coworkers have reported that LXA₄ at a concentration of 1×10^{-6} M was able to shift the log dose-response curve of LTC₄ on guinea pig lung strip to the right.²¹ Bjork and coworkers showed that LXA₄ at concentrations between 1 M and 30×10^{-6} M produced a dose-dependent contraction of human bronchi and antagonised LTC₄-induced

contractions.²² These studies support the view that LXA₄ may act as a partial agonist at the same or similar site as the sulphidopeptide leukotrienes.

The fact that 15-lipoxygenase is abundant in lung tissue and that LXA₄ has been recovered in the bronchoalveolar lavage fluid of patients with asthma and other lung diseases suggests that LXA₄ may be a potential mediator or modulator of inflammation in the lung. In a recent study eight subjects underwent inhalation challenge with LXA₄,²³ but no effect was seen on specific conductance, rate of airflow at 25% vital capacity ($\dot{V}_{25}$), blood pressure, pulse, or asthmatic symptoms. There was, however, a significant shift of the specific conductance and $\dot{V}_{25}$ dose-response curve to the right after inhalation challenge with LTC₄ combined with LXA₄ compared with that after inhalation challenge with LTC₄ alone. Thus, LXA₄ may modulate LTC₄-induced airway obstruction in vivo and may act as an endogenous sulphidopeptide leukotriene receptor antagonist.

Further evidence for the anti-inflammatory properties of LXA₄ was suggested by the finding that prior exposure of neutrophils or eosinophils to 10^{-9} – 10^{-6} M LXA₄ inhibited the chemotactic responsiveness to LTB₄, formyl-methionyl-leucyl-phenylalanine (FMLP), and plasma activating factor in a dose-dependent manner.^{24,25} The finding that LXA₄ attenuated LTB₄-induced neutrophil migration and plasma leakage in the hamster cheek pouch model also supports its putative anti-inflammatory role.²⁶

There is limited information on the mechanisms for the inhibiting effects of LXA₄ on neutrophil functions. The inhibition of chemotactic responses was associated with a concentration-dependent inhibition of phosphoinositide hydrolysis and calcium mobilisation.²⁷ There was no effect on specific binding of [³H] LTB₄ to neutrophils following preincubation with LXA₄, suggesting that the mechanism of the chemotactic factor-induced phosphoinositide hydrolysis was at a post-receptor level. Structure function studies on the mechanism of inhibition of LXA₄ on LTB₄-induced neutrophil migration demonstrated the importance of two adjacent free hydroxy groups in either the R or the S configuration; one hydroxy group has to be in a C-6 position, but the other hydroxy group can be in either the C-5 or the C-7 position for conferment of inhibitory activity.²⁸

Successful elucidation of the mechanism(s) for the inhibitory activity of LXA₄ may provide a novel therapeutic approach in inflammatory diseases.

Department of Allergy and
Respiratory Medicine,
UMDS, Guy's Hospital,
London SE1 9RT,
UK

TAK H LEE

- Samuelsson B. Leukotrienes: mediators of hypersensitivity reactions and inflammation. *Science* 1983;220:568–75.
- Borgeat P, Samuelsson B. Metabolism of arachidonic acid in polymorphonuclear leukocytes: structural analysis of novel hydroxylated compounds. *J Biol Chem* 1979;254:7865–8.
- Hamberg M, Samuelsson B. Prostaglandin endoperoxides. Novel transformations of arachidonic acid in human platelets. *Proc Natl Acad Sci USA* 1974;71:3400–4.
- Borgeat P, Samuelsson B. Arachidonic acid metabolism in polymorphonuclear leukocytes: effects of ionophore A23187. *Proc Natl Acad Sci USA* 1979;76:2148–52.
- Samuelsson B. Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation. *Science* 1983;220:568–75.
- Drazen JM, Austen KF, Lewis RA, Corey EJ. Comparative airway and vascular activities of leukotrienes C₁ and D in vivo and in vitro. *Proc Natl Acad Sci USA* 1980;77:4345–8.

- 7 Lam S, Chan H, LeRiche JC, Chan-Yeung M, Salari H. Release of leukotrienes in patients with bronchial asthma. *J Allergy Clin Immunol* 1988; **81**:711-7.
- 8 Taylor G, Taylor I, Black P, Turner N, Taylor I, Malby NH. Urinary leukotriene E₄ after antigen challenge and in acute asthma and allergic rhinitis. *Lancet* 1989;i:584-8.
- 9 Arm JP, O'Hickey SP, Spur BW, Lee TH. Airway responsiveness to histamine and leukotriene E₄ subjects with aspirin-induced asthma. *Am Rev Respir Dis* 1989; **140**:148-53.
- 10 Arm JP, Spur BW, Lee TH. The effect of inhaled leukotriene E₄ on the airway responsiveness to histamine in asthmatic and normal subjects. *J Allergy Clin Immunol* 1988; **82**:654-60.
- 11 Serhan CN, Hamberg M, Samuelsson B. Trihydroxytetraenes: a novel series of compounds formed from arachidonic acid in human leukocytes. *Biochem Biophys Res Commun* 1984; **118**:943-9.
- 12 Serhan CN, Hamberg M, Samuelsson B. Lipoxins: novel series of biologically active compounds formed from arachidonic acid in human leukocytes. *Proc Natl Acad Sci USA* 1984; **81**:5335-9.
- 13 Serhan CN, Hamberg M, Samuelsson B, Morris J, Wishka DG. On the stereochemistry and biosynthesis of lipoxin B. *Proc Natl Acad Sci USA* 1986; **83**:1983-7.
- 14 Serhan CN, Nicolaou KC, Webber SE, Veale CA, Dahlen SE, Puustinen TJ, et al. Lipoxin A: stereo chemistry and biosynthesis. *J Biol Chem* 1986; **261**:16340-5.
- 15 Serhan CN, Hirsch U, Palmblad J, Samuelsson B. Formation of lipoxin A by granulocytes from eosinophilic donors. *FEBS Lett* 1987; **217**:242-6.
- 16 Edenius C, Haeggstrom J, Lindgren J-A. Transcellular conversion of endogenous arachidonic acid to lipoxins in mixed human platelet-granulocyte suspensions. *Biochem Biophys Res Commun* 1988; **110**:219-21.
- 17 Lee TH, Crea AEG, Gant V, Spur BW, Marron BE, Nicolaou KC, et al. Identification of lipoxin A₄ and its relationship to the sulphidopeptide leukotrienes C₄, D₄ and E₄ in the bronchoalveolar lavage fluids obtained from patients with selected pulmonary diseases. *Am Rev Respir Dis* 1990; **141**:1453-8.
- 18 Dahlen SE, Raud J, Serhan CN, Bjork J, Samuelsson B. Biological activities of lipoxin A include lung strip contraction and dilation of arterioles in vivo. *Acta Physiol Scand* 1987; **130**:643-7.
- 19 Jacques CAJ, Spur BW, Crea AEG, Lee TH. The contractile activities of lipoxin A₄ and lipoxin B₄ for guinea-pig airway tissues. *Br J Pharmacol* 1988; **95**:562-8.
- 20 Badr KR, De Boer DK, Schwartzberg M, Serhan CN. Lipoxin A₄ antagonizes cellular and in vivo actions of leukotriene D₄ in rat glomerular mesangial cells. Evidence for competition at a common receptor. *Proc Natl Acad Sci USA* 1989; **86**:3428-42.
- 21 Dahlen SE, Franzen L, Raud J, Serhan CN, Westlund P, Wikstrom E. Actions of lipoxin A₄ and related compounds in smooth muscle preparations and on the microcirculation in vivo. *Adv Exp Med Biol* 1988; **229**:107-30.
- 22 Bjork T, Nicolaou KC, Dahlen SE. Lipoxin A₄ interacts with leukotriene C₄ in human bronchi. *Am Rev Respir Dis* 1989; **139**:A78.
- 23 Christie PE, Spur BW, Lee TH. The effects of lipoxin A₄ on airway responses in asthmatic subjects. *Am Rev Respir Dis* 1992; **145**:1281-4.
- 24 Lee TH, Horton CE, Kyan-Aung U, Haskard D, Crea AEG, Spur BW. Lipoxin A₄ and lipoxin B₄ inhibit chemotactic responses of human neutrophils stimulated by leukotriene B₄ and N-formyl-L-methionyl-L-leucyl-phenylalanine. *Clin Sci* 1989; **77**:195-203.
- 25 Soyombo O, Spur BW, Lee TH. Effects of lipoxin A₄ on chemotaxis and degranulation of human eosinophils stimulated by platelet-activating factor and N-formyl-L-leucyl-L-phenylalanine. *Allergy* 1994; **49**:230-4.
- 26 Hedqvist P, Raud J, Palmertz U, Haeggstrom J, Nicolaou KC, Dahlen SE. Lipoxin A₄ inhibits leukotriene B₄-induced inflammation in the hamster cheek pouch. *Acta Physiol Scand* 1989; **137**:571-2.
- 27 Grandordy BM, Lacroix H, Mavoungou E, Krilis S, Crea AEG, Spur BW, et al. Lipoxin A₄ inhibits phosphoinositide hydrolysis in human neutrophils. *Biochem Biophys Res Commun* 1990; **167**:1022-9.
- 28 Lee TH, Lympany P, Crea AEG, Spur BW. Inhibition of leukotriene B₄-induced neutrophil migration by lipoxin A₄: structure-function relationships. *Biochem Biophys Res Commun* 1991; **180**:1416-21.